ArticleJACC. CardioOncology2026
Divergent Effects of GnRH Agonist and GnRH Antagonist Treatment on Platelet Activity and Transcriptome.
Article in JACC. CardioOncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Do Platelets Explain Why GnRH Antagonists Are Potentially Safer From a Cardiovascular Perspective?JACC. CardioOncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate cancer is associated with increased cardiovascular risk. Among androgen deprivation therapy (ADT) modalities, the gonadotropin-releasing hormone (GnRH) antagonist relugolix appears to confer a lower risk for cardiovascular events than the GnRH agonist leuprolide.
objectivesThe aim of this prospective study was to investigate the impact of relugolix and leuprolide on platelet phenotype.
methodsPatients with prostate cancer initiating first-line ADT were prospectively enrolled. Blood samples were collected at baseline and 8 ± 4 weeks after treatment initiation. Platelet activation was assessed using flow cytometry (P-selectin, PAC-1, CD40, CD40L, and monocyte-platelet aggregates). Platelet RNA sequencing was performed to characterize treatment-associated transcriptomic changes.
resultsCompared with healthy control subjects, patients (n = 69) exhibited elevated P-selectin expression and enrichment of thromboinflammatory pathways. During leuprolide treatment (n = 40), PAC-1 expression increased compared with baseline in response to epinephrine, thrombin, adenosine diphosphate (ADP) and arachidonic acid (AA), while P-selectin increased in response to epinephrine and was higher with ADP and AA, though not statistically different. In contrast, during relugolix treatment (n = 29), AA-induced P-selectin expression and CD40 decreased. Platelet RNA sequencing in relugolix-treated patients demonstrated down-regulation of pathways associated with platelet activation and aggregation. Finally, leuprolide-treated patients on aspirin (n = 6) did not exhibit increased AA-induced platelet activation and in vitro P2Y
conclusionsProstate cancer is associated with heightened platelet activation and thromboinflammatory signaling. Treatment with leuprolide, but not relugolix, was associated with further augmented platelet activity. These findings support further studies to clarify links with platelet-mediated cardiovascular risk and the potential role of platelet-targeted strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.